Effect of CYP2C19 genotype on outcomes of treatment with ticagrelor versus clopidogrel in acute coronary syndrome patients with diabetes mellitus: A analysis in a large-scale, real-world study
The CYP2C19 genotype could be used to identify potential patients who would derive benefit from the ticagrelor-based antiplatelet strategy. Further research is warranted to trade off in bleeding complications from potent P2Y12 inhibitors.
Authors
- Zizhao Qi (ORCID: https://orcid.org/0000-0003-4427-4399)
- Hao Tian (ORCID: https://orcid.org/0000-0002-5022-0242)
- Miaohan Qiu (ORCID: https://orcid.org/0000-0003-2077-5770)
- Jing Li (ORCID: https://orcid.org/0009-0003-1181-0105)
- Xiaozeng Wang (ORCID: https://orcid.org/0000-0003-1979-0287)
- Yaling Han (ORCID: https://orcid.org/0000-0003-4569-6737)
- Yi Li (ORCID: https://orcid.org/0000-0003-0392-6661)
- Kai Xu (ORCID: https://orcid.org/0000-0002-2038-7156)
- Haiwei Liu (ORCID: https://orcid.org/0000-0001-8666-4462)
- Kun Na (ORCID: https://orcid.org/0000-0003-3679-8248)
Institutions
- General Hospital of Shenyang Military Region (CN)
- Jinzhou Medical University (CN)
Publication Details
- Journal
- European Journal of Pharmacology
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1016/j.ejphar.2025.177546
- Citations
- 2
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.78
Funders
- National Key Research and Development Program of China